Fortitude Announces T‑Cell Bispecific Program for Axial Spondyloarthritis

Key points:

• Fortitude Biomedicines introduced a preclinical bispecific antibody targeting T-cell signaling in axial spondyloarthritis
• Company-reported animal data suggest selective and durable suppression of disease-associated T-cell activity
• First-in-human studies are planned for the first half of 2027
• Clinical development leadership expanded with the appointment of a new SVP to support pipeline advancement

Fortitude Biomedicines has announced a lead preclinical program centered on a bispecific antibody designed to target T-cell signaling pathways in axial spondyloarthritis (axSpA), outlining early data and a projected timeline for clinical development.

The program is described as a first-in-class approach aimed at selectively modulating disease-associated T-cell activity, a key driver of inflammation in axSpA. While the company emphasizes T-cell signaling as the central therapeutic target, it has not disclosed specific molecular pathways or signaling nodes involved, nor detailed how the mechanism compares with existing approaches such as cytokine inhibition or JAK pathway blockade.

According to the company, preclinical studies in animal models demonstrated selective and durable suppression of disease-driven T-cell signaling. These findings are presented as evidence supporting the program’s potential, although the announcement does not include detailed information on study design, model systems, or quantitative outcomes.

Fortitude indicated that the program remains in the preclinical stage, with plans to advance into first-in-human studies in the first half of 2027. As part of its development efforts, the company also announced the appointment of Rahul Patel, MD, FACR, as Senior Vice President of Clinical Development, a move positioned to support progression of the lead program and broader pipeline activities.

The axSpA program is part of Fortitude’s wider focus on immune cell–targeting biologics, alongside an antibody–drug conjugate platform that incorporates proprietary molecular glue payloads. In framing the opportunity, the company highlighted the ongoing burden of axial spondyloarthritis, noting that a significant proportion of patients do not achieve adequate disease control with current therapies.

The announcement presents the bispecific antibody program as an early-stage effort supported by company-reported preclinical observations, with further development and clinical validation yet to be established.